Colfax

Enovis Corp. operates as a medical technology growth company. It develops clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. The firm operates through the following segments: Medical Technology and Fabrication Technology. The Medical Technology segment develops, manufactures and distributes medical devices used for rehabilitation, pain management and physical therapy. The Fabrication Technology develops, manufactures and supplies consumable products and equipment. The company was founded by Mitchell P. Rales and Steven M. Rales in 1995 and is headquartered in Wilmington, DE.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Enovis Corp. operates as a medical technology growth company. It develops clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. The firm operates through the following segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative disease. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. The company was founded by Mitchell P. Rales and Steven M. Rales in 1995 and is headquartered in Wilmington, DE.

Colfax (CFX) delivered earnings and revenue surprises of 12.82% and 4.49%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Colfax (CFX) Q1 Earnings and Revenues Top Estimates

Shares of Colfax (NYSE:CFX) were flat in pre-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 15.79% over the past year to $0.44, which beat the estimate of $0.40.

Colfax: Q1 Earnings Insights

ANNAPOLIS JUNCTION, MD, April 29, 2021 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE: CFX), a leading diversified technology company, today announced its financial results for the first quarter of 2021.

Colfax Announces First Quarter 2021 Results

Colfax (CFX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Colfax (CFX) is Poised to Beat Earnings Estimates Again

DALLAS--(BUSINESS WIRE)-- #djo--DJO today announced that it has completed the acquisition of MedShape, Inc., a privately held orthopedic medical device company founded in 2005.

DJO® Acquires MedShape, Inc.

Annapolis Junction, MD, April 14, 2021 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE: CFX), a leading diversified technology company, today announced that it will issue a press release providing financial results for the first quarter of 2021 on the morning of Thursday, April 29, 2021. The Company will hold a conference call to discuss these results beginning at 8:00 a.m. Eastern on that day, which will be open to the public by calling +1-877-303-7908 (U.S. callers) and +1-678-373-0875 (International callers) and referencing the conference ID number 1986324 and through webcast via Colfax's website www.colfaxcorp.com under the “Investors” section.

Colfax Schedules First Quarter 2021 Earnings Release and Conference Call

AUSTIN, Texas--(BUSINESS WIRE)-- #djo--DJO today announced a strategic investment in Insight Medical Systems, a technology company dedicated to wearable surgical navigation in orthopaedics.

DJO Invests in Next-Generation Augmented Reality Technology Primed for ASC Market Growth

Colfax (CFX) to redeem $700 million worth of senior notes that are due to expire in 2024 and 2026. The move will help the company to lower its debt balance.

Colfax (CFX) to Redeem $700M Worth Senior Notes Due 2024 & 2026

Annapolis Junction, MD, March 25, 2021 (GLOBE NEWSWIRE) -- Colfax Corporation (“Colfax” or the “Company”) (NYSE: CFX), a leading diversified technology company, announced today that it has given notice of its intention to redeem $600 million principal amount representing all of its outstanding 6.000% Senior Notes due 2024 (CUSIP Numbers 15723RAA2, U1581TAA6) (the “2024 Notes”) and $100 million of the $400 million outstanding principal amount of its 6.375% Senior Notes due 2026 (CUSIP Numbers 15723RAC8, U1581TAB4) (the “2026 Notes” and, together with the 2024 Notes, the “Notes”) on April 24, 2021 (the “Redemption Date”). The 2024 Notes will be redeemed at a redemption price of 103.000% of the principal amount of the 2024 Notes and the 2026 Notes will be redeemed at a redemption price of 106.375% of the principal amount of the 2026 Notes to be redeemed, plus, in each case, accrued and unpaid interest to, but not including, the Redemption Date.  On and after the Redemption Date, interest will cease to accrue on the 2024 Notes and the portion of the 2026 Notes selected for redemption.  After the Redemption Date, upon surrender of the 2026 Notes, new 2026 Notes in principal amount equal to the unredeemed portion of the original 2026 Notes will be issued in the names of the holders thereof.

Colfax Announces Full Redemption of 6.000% Senior Notes due 2024 and $100 Million Partial Redemption of 6.375% Senior Notes due 2026

Colfax (CFX) reported earnings 30 days ago. What's next for the stock?

Why Is Colfax (CFX) Up 10.6% Since Last Earnings Report?

ANNAPOLIS JUNCTION, MD, March 16, 2021 (GLOBE NEWSWIRE) -- Colfax Corporation (“Colfax” or the “Company”) (NYSE: CFX), a leading diversified technology company, announced today the pricing of an underwritten registered public offering of 14,000,000 shares of its common stock at a public offering price of $46.00 per share. The underwriters have a 30-day option to purchase up to an additional 2,100,000 shares from the Company at the public offering price. The Company estimates that the net proceeds from the offering, after deducting the underwriting discounts and commissions and other estimated offering expenses, will be approximately $618.4 million, or $711.3 million if the underwriters exercise their option to purchase additional shares in full. The shares are expected to be delivered on or about March 19, 2021, subject to customary closing conditions.

Colfax Announces Pricing of Public Offering of 14,000,000 Shares of Common Stock

Colfax (CFX) offers 14 million common shares to the public in an underwritten offer. The funds raised will be used for funding general corporate purposes and working capital needs.

Colfax (CFX) Commences Public Offering of 14M Common Shares

ANNAPOLIS JUNCTION, MD, March 15, 2021 (GLOBE NEWSWIRE) -- Colfax Corporation (“Colfax” or the “Company”) (NYSE: CFX), a leading diversified technology company, announced today that it has commenced an underwritten registered public offering of 14,000,000 shares of its common stock. In addition, Colfax intends to grant the underwriters a 30-day option to purchase up to an additional 2,100,000 shares of its common stock. The offering is subject to market and other customary conditions.

Colfax Announces Public Offering of 14,000,000 Shares of Common Stock

Colfax's (CFX) plan of dividing its fabrication technology and medical technology businesses into two separate companies will likely unlock significant values for each of its businesses.

Colfax (CFX) Plans to Split Businesses Into Separate Companies

Colfax (CFX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Colfax (CFX) Moves 5.8% Higher: Will This Strength Last?

Annapolis Junction, Maryland, March 04, 2021 (GLOBE NEWSWIRE) --  – Colfax Corporation (NYSE: CFX), a leading diversified technology company, today announced its intention to separate its fabrication technology and specialty medical technology businesses into two differentiated, independent, and publicly-traded companies. The separation is intended to be structured in a tax-free manner and is targeted to be completed in the first quarter of 2022.

Repeat: Colfax Announces Intention to Separate Into Two Independent Public Companies

Colfax Announces Intention to Separate Into Two Independent Public Companies

Annapolis Junction, MD, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE: CFX), a leading diversified technology company, today announced that it has appointed Philip Okala, Chief Operating Officer of the University of Pennsylvania Health System, to its Board of Directors. This appointment increases the size of Colfax's Board of Directors to eleven members.

Philip Okala Appointed to Colfax Board of Directors

Colfax's (CFX) Q4 earnings decrease year over year, reflecting the impacts of weak sales generation and a decline in margins. For 2021, it anticipates y/y revenue and earnings growth.

Colfax (CFX) Q4 Earnings Top Estimates, 2021 View Impressive

Colfax Corporation (CFX) CEO Matt Trerotola on Q4 2020 Results - Earnings Call Transcript

Colfax (CFX) delivered earnings and revenue surprises of 4.08% and -0.25%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Colfax (CFX) Surpasses Q4 Earnings Estimates

Shares of Colfax (NYSE:CFX) rose 0.2% in pre-market trading after the company reported Q4 results. Quarterly Results Earnings per share fell 16.39% year over year to $0.51, which beat the estimate of $0.50.

Colfax: Q4 Earnings Insights

•         Reported $0.29 EPS from continuing operations and achieved $0.51 of adjusted EPS•         Recently acquired two high-growth, high-gross margin medical technology businesses  •         Announced 2021 outlook with expectations for significant revenue, profit and cash flow growth •         Scheduled Investor Day for Thursday, March 11, 2021

Colfax Announces Fourth Quarter 2020 Results and 2021 Growth Outlook

Annapolis Junction, MD, Jan. 29, 2021 (GLOBE NEWSWIRE) -- Colfax Corporation (NYSE: CFX), a leading diversified technology company, today announced that it will issue a press release providing financial results for the fourth quarter of 2020 on the morning of Thursday, February 18, 2021. The Company will hold a conference call to discuss these results beginning at 8:00 a.m. Eastern on that day, which will be open to the public by calling +1-877-303-7908 (U.S. callers) and +1-678-373-0875 (International callers) and referencing the conference ID number 3753307 and through webcast via Colfax's website www.colfaxcorp.com under the “Investors” section.

Colfax Schedules Fourth Quarter 2020 Earnings Release and Conference Call

Amphastar Pharma

Evoqua Water Technologies

Barings BDC Inc

Biohaven Pharmaceutical Hld

Crh Medical

Global Blood Therapeutics

Hannon Armstrong Sustainable Infrastructure Capital

Houghton Mifflin Harcourt

Lexicon Pharmaceuticals

MannKind

Nektar Therapeutics

Nano-X Imaging

ObsEva

Personalis Inc

PIMCO Corporate & Income Opportunity Fund

Construction Partners

Surgery Partners

SP Plus

Takeda Pharmaceutical

Cohen & Steers Infrastructure Fund Inc

Xerium Technologies

A recap for my 20/20 Vision is offered for my readers. I will share my concerns about the current market conditions.

News for Colfax Stock (CFX)